This raises the question of how SPG302 can restore synaptic density and cognition in the context of high levels of phospho-Tau, particularly when the animal model used expresses the P301L mutation that is known to induce synapse loss in other tauopathy models as well [78]. The gene discussed is MAPT; the disease is tauopathy.